<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3727">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04429854</url>
  </required_header>
  <id_info>
    <org_study_id>S63992</org_study_id>
    <nct_id>NCT04429854</nct_id>
  </id_info>
  <brief_title>Donated Antibodies Working Against nCoV</brief_title>
  <acronym>DAWN-Plasma</acronym>
  <official_title>A Randomized, Open-label, Adaptive, Proof-of-concept Clinical Trial of Donated Antibodies Working Against With COVID-19: DAWN-PLASMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal Knowledge Centre (KCE)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a phase II, proof-of-concept study. In the present study, we investigate if the&#xD;
      administration of blood-plasma from patients recovered from COVID-19, could be effective to&#xD;
      treat patients who are severely ill because of a COVID-19 infection. The general idea behind&#xD;
      the transfusion, is that plasma of recovered patients contains antibodies that could&#xD;
      eliminate the novel coronavirus causing COVID-19, and lead to a less severe course of the&#xD;
      disease, or a faster healing. Simply put, in this study we would like to investigate whether&#xD;
      'borrowed immunity' from a person who has cured from this disease, could be applied to cure&#xD;
      other patients more rapidly.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In December 2019, a new coronavirus (the SARS-CoV-2 virus) emerged, which spread fast across&#xD;
      the world, and has led to a pandemic. The disease caused by this virus, called COVID-19, has&#xD;
      a mild course in a high number of infected people, but is known to have a more severe course&#xD;
      in some. Currently, there are no successful treatments with a known effect on the course of&#xD;
      the disease in patients suffering from COVID-19. In this study, we will examine whether&#xD;
      plasma, a treatment that has been used in human subjects for other diseases (and is known to&#xD;
      be safe), can be used to influence the course of COVID-19 towards a lower severity.&#xD;
&#xD;
      The aim of the study is to evaluate clinical efficacy and safety of convalescent plasma for&#xD;
      COVID-19.&#xD;
&#xD;
      This clinical trial is an adaptive, randomized, open-label phase II proof-of-concept study to&#xD;
      investigate the safety and effect of potentially interesting treatments, for the treatment of&#xD;
      hospitalized adult patients suffering from COVID-19.&#xD;
&#xD;
      Because an active treatment for COVID-19 is lacking, plasma donation is now being proposed.&#xD;
      To investigate this effect of plasma, we will compare two groups of patients. One group will&#xD;
      get standard treatment, plus plasma from a patient recently cured from COVID-19. A second&#xD;
      group will get standard treatment alone. In this study, 2 patients out of 3 will receive&#xD;
      plasma, and 1 patient out of 3 will receive standard treatment alone. After the study, we&#xD;
      will be able to establish whether plasma donation is useful or not.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2, 2020</start_date>
  <completion_date type="Anticipated">November 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>483 patients with 2:1 randomization. 322 patients receiving Convalescent Plasma - 161 patients receiving Standard of Care</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients requiring mechanical ventilation or death</measure>
    <time_frame>No mechanical ventilation at day 15 after hospitalization.</time_frame>
    <description>Primary outcome of the study is the number of patients alive without mechanical ventilation at day 15 after hospitalization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical status of subject at day 15 and day 30 (on a 10-point &quot;WHO progression&quot; ordinal scale)</measure>
    <time_frame>day 15 and day 30</time_frame>
    <description>0. Uninfected. Non viral RNA detected&#xD;
Ambulatory, Asymptomatic, viral RNA detected&#xD;
Ambulatory, Symptomatic, Independent&#xD;
Ambulatory, Symptomatic, Assistance needed&#xD;
Hospitalized, mild disease, No oxygen therapy needed&#xD;
Hospitalized, mild disease, Oxygen by mask of nasal prongs&#xD;
Hospitalized, severe disease, Oxygen by NIV or High flow&#xD;
Hospitalized, severe disease, Intubation and mechanical ventilation (pO2/FiO2&gt;=150 OR SpO2/FIO2&gt;=200)&#xD;
Hospitalized, severe disease, Mechanical ventilation (pO2/FiO2&lt;150 OR SpO2/FIO2&lt;200) OR vasopressors (norepinephrine &gt;0.3 microg/kg/min)&#xD;
Hospitalized, severe disease, Mechanical ventilation pO2/FiO2&lt;150 AND vasopressors (norepinephrine &gt;0.3 microg/kg/min), OR Dialysis OR ECMO&#xD;
Death, Dead</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">483</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Convalescent Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 units of convalescent plasma:&#xD;
2 units of plasma are administered within 12h after randomization, but preferably as soon as practically possible&#xD;
2 units of plasma should be administered between 24h and 36h after the first infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive. Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent Plasma</intervention_name>
    <description>4 units of convalescent plasma:&#xD;
2 units of plasma are administered within 12h after randomization, but preferably as soon as practically possible&#xD;
2 units of plasma should be administered between 24h and 36h after the first infusion&#xD;
Other investigational products may be added as part of the adaptive study design.</description>
    <arm_group_label>Convalescent Plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Since there are no current approved treatment options for COVID-19, the standard of care is mostly supportive.</description>
    <arm_group_label>Convalescent Plasma</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject (≥18 years old) or legally authorized representative provides informed consent&#xD;
             prior to initiation of any study procedures.&#xD;
&#xD;
          2. Subject (or legally authorized representative) understands and agrees to comply with&#xD;
             planned study procedures.&#xD;
&#xD;
          3. Male or non-pregnant female adult ≥18 years of age at time of enrolment.&#xD;
&#xD;
          4. Patient should be hospitalized&#xD;
&#xD;
          5. Has a confirmed diagnosis of SARS-CoV-2 infection, defined as either:&#xD;
&#xD;
               1. laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other&#xD;
                  commercial or public health assay in any specimen as diagnosed within 60 hours&#xD;
                  prior to randomization or&#xD;
&#xD;
               2. The combination of upper or lower respiratory infection symptoms (fever, cough,&#xD;
                  dyspnea, desaturation) and typical findings on chest CT scan and absence of other&#xD;
                  plausible diagnoses&#xD;
&#xD;
          6. Illness of any duration, and at least one of the following:&#xD;
&#xD;
               1. Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), or&#xD;
&#xD;
               2. Clinical assessment (evidence of rales/crackles on exam) AND SpO2 ≤ 94% on room&#xD;
                  air, or&#xD;
&#xD;
               3. Requiring supplemental oxygen.&#xD;
&#xD;
          7. ABO D typing of the patient should be done at least once and the result should be&#xD;
             known.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receiving invasive (any mode where a patient has been intubated endotracheally, or via&#xD;
             tracheostomy) or non-invasive (for instance, but not restricted to CPAP, PSV, PCV,&#xD;
             SiMV) mechanical ventilation before or upon randomization.&#xD;
&#xD;
          2. Pregnancy or breast feeding.&#xD;
&#xD;
          3. Any medical condition which would impose an unacceptable safety hazard by&#xD;
             participation to the study.&#xD;
&#xD;
          4. Patients with a documented grade 3 allergic reaction after the administration of fresh&#xD;
             frozen plasma (i.e. systemic reaction with cardiovascular and/or respiratory&#xD;
             involvement)&#xD;
&#xD;
          5. Patients that have treatment restriction that excludes mechanical ventilation and/or&#xD;
             endotracheal intubation&#xD;
&#xD;
          6. Rituximab or another anti-CD20 monoclonal antibody (f.ex. obinutuzumab) has been&#xD;
             administered during the year prior of the date of admission.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert Meyfroidt, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ZNA</name>
      <address>
        <city>Antwerpen</city>
        <zip>2050</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis Bonheiden</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bordet</name>
      <address>
        <city>Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Sint-Pieter</name>
      <address>
        <city>Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussel</city>
        <zip>1030</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Ziekenhuis</name>
      <address>
        <city>Brussel</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc</name>
      <address>
        <city>Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Vincentius</name>
      <address>
        <city>Deinze</city>
        <zip>9800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Lucas</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHC Liège Mont Légia</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liège Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Jolimont Mons-Hainaut</name>
      <address>
        <city>Mons</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint-Trudo Ziekenhuis</name>
      <address>
        <city>Sint-Truiden</city>
        <zip>3800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Wallonie Picarde (CHwapi)</name>
      <address>
        <city>Tournai</city>
        <zip>7500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 27, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT04429854/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 12, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT04429854/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

